Enable Injections, Inc. (“Enable”), a healthcare innovation company developing and manufacturing the enFuse® wearable drug ...

This wearable delivery system enables large-volume, high-viscosity subcutaneous drug administration in either clinical settings or home self-administration.” Cincinnati-based Enable Injections ...

Hooven, Chairman and CEO of Enable Injections. "Our enFuse platform is uniquely positioned to address challenges in developing large-volume subcutaneous oncology drugs. This wearable delivery system ...

Bristol Myers Squibb's Opdivo has been approved in a subcutaneous injection formulation by ... original IV formulations improves the ease of administration for the drugs, reducing the time ...

The initial loading dose is 3 mg/kg administered via subcutaneous injection once weekly for the first four weeks ... offering ...

Approximately two-thirds of patients responded to teduglutide, which is sold under the brand name Gattex as a treatment for ...

The US Food and Drug Administration (FDA) has approved a pre-filled syringe version of argenx’s Vyvgart, giving generalised ...

One day after a subcutaneous injection into the left thigh ... Instruct patients to avoid administering etanercept to the area of ISR. Future injections should be given at least one inch from ...

A formulation of MSD's cancer drug Keytruda that can be given by subcutaneous injection rather than intravenous infusion has cleared a phase 3 trial, setting up approvals later this year.

Andrew Kuykendall, MD, is an investigator on the phase 3 VERIFY trial (NCT05210790), findings from which demonstrate the safety, reliability, and effectiveness of rusfertide to treat polycythemia vera ...

Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and ...